Abstract
Summary Botulinum toxin type A has recently become a treatment option in the management of spasticity in children with cerebral palsy. Intramuscular injections of botulinum toxin A block the release of acetylcholine at the motor end plate, leading to reversible chemodenervation of muscle. This has been shown to provide a clinically useful reduction in localised spasticity for 12-16 weeks with flow-on into more long-term improvements in function in about 5% of children (termed golden responders). This review discusses the role of botulinum toxin A in the management of spasticity in children with cerebral palsy, to help therapists to select appropriate patients and maximise the potential gains from botulinum toxin A treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
